An Indispensable Partner

To fulfill the promise of on-target gene editing from discovery to patient

[ Company Overview ]

Physicians and regulators are concerned that changes to a patient’s genome might have unintended, life-altering consequences

It will be imperative to understand the off-target risk profile of your therapy to inform regulatory filings, support patient and clinician decision making, and to conduct post market surveillance

Invaluable gene editing off-target insights from initial research to patient therapies

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.

Discovery features
Development features
Commercialization features

SeQure Dx comprehensively evaluates and confirms on- and off-target events using proprietary analytical tools that deliver unparalleled sensitivity and scalability.

Our diagnostics are editor-agnostic and scalable — providing both individual and population level insight.

Join the team – help us make safe gene editing a reality

Come join an energetic, focused, and dynamic team that supports career growth as well as personal well-being.

  • KromaTiD and SeQure Dx enter partnership agreement to offer comprehensive, IND-enabling gene editing services supporting cell and gene therapy research

    KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development. Full Release ❯

  • SeQure Dx to present at American Society of Gene and Cell Therapy (ASGCT) on the importance of incorporating population heterogeneity evaluation into gene editing and cell therapy off-target analyses

    SeQure Dx, Inc, a leading genomics intelligence company, announced today it will present new data at the 2023 American Society of Gene and Cell Therapy Annual Meeting from May 16 - 20 in Los Angeles.Full Release ❯